Company: NCEL
Filing Date: 2025-09-10
Form Type: 424B3
Source: 0001213900-25-086600
Chunk: 793

Company: NewcelX Ltd.
Filing Date: 2025-09-10
Form: 424B3
Chunk 793
---
 royalties received from sublicensees, ranging between 5% Annex F-27 NLS PHARMACEUTICS LTD. AND SUBSIDIARIES NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

and 15% which may decrease or increase up to 30% if the Company challenges the validity of the patents under the agreement, depending on the result of such challenge. For the year ended December 31, 2024, the Company recorded fees to Aexon of $170,000 which is included in research and development expenses on the statement of operating and comprehensive loss. In October 2024, the Company entered into a consulting agreement with Ms. Nicole Fernandez -McGovern, the Company’s current Chief Financial Officer, pursuant to which the Company agreed to pay Mr. Fernandez -McGoverna monthly retainer for her services of $18,000 per month. For the year ended December 31, 2024, the Company recorded fees to Ms. Fernandez -McGovernof $54,316 which is included in general and administrative expenses on the statement of operating and comprehensive loss. Note 13 Revisions of previously issued financial statements: The Company identified an error in the classification of preferred shares and common shares within shareholders’ equity on the Consolidated Balance Sheets as of December 31, 2024. The error was limited to the line item presentation of “preferred shares” and “common shares” and did not affect total shareholders’ equity (deficit), the consolidated statements of operations, the consolidated statements of equity, the consolidated statements of cash flows, or any other financial statement captions. The Consolidated Balance Sheets have been revised to correct the presentation of preferred shares and common shares as of December 31, 2024. The table below summarizes the effect of the revision correcting the error on the Company’s previously issued financial statements as of December 31, 2024:

| Shareholders’ Equity (Deficit)                                                                              |     | As Previously 
 Reported      |             |   |     | Adjustment |            |   |     | As      
 Revised |             |   |
|:------------------------------------------------------------------------------------------------------------|:----|:--------------|------------:|:--|:----|:-----------|-----------:|:--|:----|:--------|------------:|:--|
| Preferred shares, CHF 0.80 par value, 206,452 registered shares issued and outstanding at December 31, 2024 |     | $             |   2,740,958 |   |